305 related articles for article (PubMed ID: 16188301)
41. The identification and management of hereditary breast and ovarian cancer.
Scalia JL; Legare RD
Med Health R I; 2003 Feb; 86(2):48-51. PubMed ID: 12666278
[No Abstract] [Full Text] [Related]
42. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
43. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.
Piek JM; Dorsman JC; Zweemer RP; Verheijen RH; van Diest PJ; Colgan TJ
Int J Gynecol Pathol; 2003 Jul; 22(3):315-6; author reply 315-6. PubMed ID: 12819403
[No Abstract] [Full Text] [Related]
44. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
45. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
46. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
47. [Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation].
Dijkhuizen FP; Huisman A; Boonstra H; Aalders AL
Ned Tijdschr Geneeskd; 2003 May; 147(18):877-9. PubMed ID: 12756880
[TBL] [Abstract][Full Text] [Related]
48. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
49. Familial ovarian cancer.
Volm T
Curr Womens Health Rep; 2002 Feb; 2(1):34-8. PubMed ID: 12112981
[TBL] [Abstract][Full Text] [Related]
50. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
51. Oophorectomy in carriers of BRCA mutations.
Anderson WF; Brawley OW; Chang S
N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
[No Abstract] [Full Text] [Related]
52. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
53. One-hit effects and cancer.
Iniesta MD; Chien J; Wicha M; Merajver SD
Cancer Prev Res (Phila); 2010 Jan; 3(1):12-5. PubMed ID: 20051368
[TBL] [Abstract][Full Text] [Related]
54. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
55. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
56. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
[TBL] [Abstract][Full Text] [Related]
57. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
58. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
59. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
60. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
Preisler-Adams S; Schönbuchner I; Fiebig B; Welling B; Dworniczak B; Weber BH
Cancer Genet Cytogenet; 2006 Jul; 168(1):44-9. PubMed ID: 16772120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
